Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL

This review presents a comprehensive analysis of actual ambulatory care in patients with type 2 diabetes mellitus provided in 10 federal subjects withinthe period of 1 year. The analysis is based on results from non-interventional open label prospective observational study DIA-CONTROL, whichincluded...

Full description

Saved in:

Bibliographic Details
Main Author:	Marina Vladimirovna Shestakova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2011-12-01
Series:	Сахарный диабет
Subjects:	prospective observational study treatment type 2 diabetes mellitus dpp-4 inhibitors
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5822
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register)
by: E. Yu. Andreenko, et al.
Published: (2019-12-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Control of type 2 diabetes mellitus: problems and prospects for their solution
by: Tatiana Ivanovna Romantsova, et al.
Published: (2009-12-01)

A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
by: Marina Vladimirovna Shestakova
Published: (2012-03-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS
by: Martina Kurnia Rohmah
Published: (2018-03-01)

Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry
by: Ivan Ivanovich Dedov, et al.
Published: (2017-05-01)

The Diketopyrrolopyrrole (DPP) Core as a Gel-Forming Material: Current Status and Untapped Potential
by: Abelardo Sánchez-Oliva, et al.
Published: (2025-02-01)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
by: D. V. Kurkin, et al.
Published: (2023-02-01)

Is cardiovascular risk factors prevention necessary from childhood? What do prospective studies show
by: A. A. Alexandrov, et al.
Published: (2016-04-01)

Prevalence and Prognostic Significance of Chloride Levels in Patients with Acute Medical Conditions: A Prospective Observational Study
by: Rhita Bennis Nechba, et al.
Published: (2025-04-01)

Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive
by: Marina Vladimirovna Shestakova
Published: (2012-12-01)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
by: Anna A. Mosikian, et al.
Published: (2018-11-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study
by: Itsukaichi A, et al.
Published: (2025-01-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Taurine as a supplement for treating type II diabetes mellitus with metformin and DPP4 inhibitor
by: Tianyichen Xiao, et al.
Published: (2025-05-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
by: Yu Tian, et al.
Published: (2023-12-01)

PROGNOSTIC FACTORS OF CARDIAC COMPLICATIONS AFTER ISCHEMIC STROKE (BY THE RESULTS OF PROSPECTIVE STUDY)
by: V. A. Shandalin, et al.
Published: (2014-10-01)

Hypotension and survival: diagnostic criteria in Russian and United States population
by: V. G. Vilkov, et al.
Published: (2021-06-01)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01)

National register of diabetes mellitus in Russian Federation.
by: Ivan Ivanovich Dedov, et al.
Published: (2015-10-01)

Genetic mechanisms of disorders in the metabolism of polyunsaturated fatty acids in the development of chronic inflammation in bronchial asthma
by: O. Yu. Kytikova, et al.
Published: (2025-07-01)

Elevated activity of plasma dipeptidyl peptidase 4 upon stress can be targeted to reverse tumor immunosuppression
by: Peipei Li, et al.
Published: (2025-05-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment
by: Dina Azkiyah, et al.
Published: (2025-05-01)

Phytochemical and Bioactivity Analysis of Several Methanolic Extracts of Nine Bryophytes Species
by: Ebru Kocadağ Kocazorbaz, et al.
Published: (2021-08-01)

Contribution of hypertension and other risk factors to survival and mortality in the Russian population
by: Yu. A. Balanova, et al.
Published: (2021-09-01)

Diabetes mellitus as an economic problem in Russian Federation
by: Ivan Ivanovich Dedov, et al.
Published: (2016-01-01)

A randomized controlled trial of fruit meal sequence with low, moderate, and high glycemic indexes among type 2 diabetes mellitus patients
by: Dono Indarto, et al.
Published: (2024-12-01)

Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study
by: En-Wei Chang, et al.
Published: (2025-06-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)